Blog
RSS FeedPosted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...
Posted by Michael Wonder on 19 Sep 2024
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia. ...
Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...
Posted by Michael Wonder on 12 Sep 2024
Empagliflozin for the treatment of adolescents with type 2 diabetes mellitus
12 September 2024 - NICE is unable to make a recommendation on the use of empagliflozin (Jardiance) in the NHS for ...
Posted by Michael Wonder on 12 Sep 2024
Futibatinib for previously treated patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 ...
Posted by Michael Wonder on 12 Sep 2024
Faricimab for the treatment of patients with visual impairment caused by macular oedema after retinal vein occlusion
11 September 2024 - NICE has published final evidence-based recommendations on the use of faricimab (Vabysmo) for the treatment of ...
Posted by Michael Wonder on 11 Sep 2024
Exagamglogene autotemcel for the treatment of patients 12 years of age and older with transfusion-dependent beta-thalassaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...
Posted by Michael Wonder on 11 Sep 2024
Evinacumab for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of evinacumab (Evkeeza) for the treatment of ...
Posted by Michael Wonder on 05 Sep 2024
Adults with von Hippel-Lindau disease to benefit from new treatment
5 September 2024 - NICE has recommended belzutifan for some adults with von Hippel-Lindau disease, in final draft guidance, which could ...
Posted by Michael Wonder on 04 Sep 2024
Zanubrutinib for the treatment of patients with marginal zone lymphoma after anti-CD20-based treatment
4 September 2024 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 04 Sep 2024
Iptacopan hydrochloride for the treatment of patients with paroxysmal nocturnal haemoglobinuria
4 September 2024 - NICE has published final evidence-based recommendations on the use of iptacopan hydrochloride (Fabhalta) for the treatment ...
Posted by Michael Wonder on 04 Sep 2024
Vibegron for the treatment of patients with symptoms of overactive bladder syndrome
4 September 2024 - NICE has published final evidence-based recommendations on the use of vibegron (Obgemsa) for the treatment of ...
Posted by Michael Wonder on 29 Aug 2024
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- ...
Posted by Michael Wonder on 25 Aug 2024
Risankizumab for the treatment of patients with moderately to severely active ulcerative colitis
23 August 2024 - NICE has published final evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of ...
Posted by Michael Wonder on 22 Aug 2024
Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS
22 August 2024 - Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, ...